Analysts expect NuVasive, Inc. (NASDAQ:NUVA) to post $260.59 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for NuVasive’s earnings. The lowest sales estimate is $259.30 million and the highest is $261.59 million. NuVasive posted sales of $249.86 million during the same quarter last year, which would indicate a positive year over year growth rate of 4.3%. The business is expected to announce its next earnings results on Tuesday, April 24th.
On average, analysts expect that NuVasive will report full-year sales of $260.59 million for the current fiscal year, with estimates ranging from $1.09 billion to $1.10 billion. For the next year, analysts expect that the firm will post sales of $1.15 billion per share, with estimates ranging from $1.15 billion to $1.17 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow NuVasive.
NuVasive (NASDAQ:NUVA) last released its earnings results on Monday, February 26th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.56. The company had revenue of $271.70 million during the quarter, compared to analyst estimates of $272.11 million. NuVasive had a net margin of 8.06% and a return on equity of 13.40%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.53 EPS.
In related news, CEO Gregory T. Lucier acquired 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were bought at an average price of $50.30 per share, with a total value of $301,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Xact Kapitalforvaltning AB acquired a new stake in shares of NuVasive during the fourth quarter worth about $293,000. MetLife Investment Advisors LLC acquired a new stake in shares of NuVasive during the fourth quarter worth about $3,272,000. Westside Investment Management Inc. lifted its holdings in shares of NuVasive by 76.0% during the fourth quarter. Westside Investment Management Inc. now owns 2,640 shares of the medical device company’s stock worth $147,000 after purchasing an additional 1,140 shares during the period. Macquarie Group Ltd. acquired a new stake in shares of NuVasive during the fourth quarter worth about $19,094,000. Finally, Meadow Creek Investment Management LLC lifted its holdings in shares of NuVasive by 22.0% during the fourth quarter. Meadow Creek Investment Management LLC now owns 7,344 shares of the medical device company’s stock worth $429,000 after purchasing an additional 1,326 shares during the period.
NuVasive (NASDAQ NUVA) opened at $50.74 on Wednesday. NuVasive has a 52 week low of $44.62 and a 52 week high of $81.68. The company has a quick ratio of 1.94, a current ratio of 3.48 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $2,600.00, a P/E ratio of 43.74, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50.
WARNING: “NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $260.59 Million” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/nuvasive-inc-nuva-expected-to-post-quarterly-sales-of-260-59-million.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.